KP Tissue Inc. (TSX:KPT)
Canada flag Canada · Delayed Price · Currency is CAD
11.48
+0.08 (0.70%)
May 12, 2026, 3:59 PM EST
← View all transcripts

Earnings Call: Q1 2022

May 12, 2022

Operator

Thank you for standing by. Welcome to KP Tissue First Quarter 2022 Results Conference Call. At this time, all participants are in a listen-only mode. Following the presentation, we will conduct a question-and-answer session, and instructions will be provided at that time for you to queue up for questions. If anyone has any difficulties hearing the conference, please press star followed by zero for operator assistance at any time. Before turning the meeting over to management, I would like to remind everyone that this conference call is being recorded on Thursday, May 12th, 2022. I will now turn the conference over to Mr. Mike Baldesarra, Director, Investor Relations. Please go ahead.

Mike Baldesarra
Director of Investor Relations, KP Tissue Inc

Thank you, operator, and good morning, ladies and gentlemen. My name is Mike Baldesarra. I'm the Director of Investor Relations at KP Tissue Inc. The purpose of the conference call is to review the financial results for the first quarter of 2022 for Kruger Products, which I'll refer to as KPLP going forward. With me this morning is Dino Bianco, the Chief Executive Officer of KP Tissue and Kruger Products LP, and Mark Holbrook, the Chief Financial Officer of KP Tissue and Kruger Products LP. The following discussions and responses to questions contain forward-looking statements concerning the company's activities. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the company's actual results to differ materially from those in the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements.

The company does not undertake to update these forward-looking statements, except as required by applicable laws. There is a page at the beginning of the written presentation, which contains the usual legal cautions, including as to forward-looking information, which you should be aware of. I'd like to point out that all the figures expressed in today's call are in Canadian dollars, unless otherwise stated. The press release reporting our Q1 2022 results were published this morning and will be accessible from our website at kptissueinc.com.

Please be aware that our MD&A will be posted on the website and will also be available on SEDAR. Finally, I'd like to ask that during the call to refer to the presentation we've prepared to accompany these discussions, which is also available on the website. We'd also appreciate that during the Q&A period for you to limit your questions to two. Thank you for your collaboration, ladies and gentlemen. I'll now turn the call over to Dino Bianco, our CEO. Dino?

Dino Bianco
CEO, KP Tissue Inc

Thank you, Mike. Good morning, everyone, and thank you for joining us for our first quarter earnings call. We continued to deliver strong sales growth in the first quarter of 2022, driven by ongoing market recovery, new Sherbrooke capacity, and price increases affecting all our businesses and regions. Robust top-line growth was tempered by escalating inflation across many parts of our business, which significantly impacted Adjusted EBITDA in the first quarter. To counter inflationary pressure, we have adopted a multifaceted strategy, which I will outline a little later in my prepared remarks. Now, let's take a look at our financial performance on slide slide.

Revenue growth of 28.5% in the first quarter of 2022 mainly reflects the Q3 2021 selling price increase in consumer Canada and pricing in consumer US and AFH, along with higher sales volume in the consumer segment compared to a really relatively soft quarter in 2021. The AFH segment also benefited from higher sales volume in the first quarter of 2022 versus Q1 2021, as the business continues to recover from the impact of COVID-19. From a geographic perspective, revenue in Canada increased 24.8% year-over-year, while the US surged 34.6%.

In terms of profitability, Adjusted EBITDA decreased to CAD 29.1 million in the first quarter of 2022, mainly due to the unfavorable effect of sales mix and overhead absorption, higher fiber prices and other inflationary pressure, along with some operational issues in our Memphis facility. These factors were partially offset by the higher sales volume and the selling price increases. Pulp and BEK average prices in Canadian dollars continued to increase. I'll go off script here to say you can look at the chart. We are in uncharted territory as we look at pulp pricing and the impact that has had both on BEK and NBSK. Pulp or fiber as a whole is not the only cost item being impacted by inflationary pressure, as shown on slide 7.

Freight and natural gas prices soared more than 35% and 50%, respectively, in the first quarter of 2022 compared to the same period in 2021. Packaging costs, meanwhile, increased more than 15% year-over-year, while labor costs climbed roughly 5% in the first quarter. To counter such inflationary pressure, we have adopted a multifaceted strategy, including additional price increases across all our segments, SG&A cuts, incremental productivity programs, reductions in working capital, and deferring discretionary capital spending. We believe that price increases, combined with cost-saving initiatives, should begin mitigating inflation in the second half of the year. Moving on to our network modernization slides on page 8 and 9, TAD Sherbrooke continues to exceed ramp-up expectations.

In terms of our Sherbrooke expansion project, we now anticipate that the bathroom tissue line will start up in Q1 2023, while other assets are on track for later in 2023 and 2024. Turning to our network in Memphis, selling has been very strong for our new facial tissue line, but the startup has been pushed out to the third quarter due to global supply chain issues affecting our ability to secure equipment. We have committed more than $20 million to this new facial line, which will provide future growth opportunities in the US market. In terms of our Memphis operations, we anticipate labor challenges will continue affecting productivity in the first half of 2022. Staff availability is improving, but it takes time to train new employees on this equipment. We have also endured some equipment challenges, which has delayed our turnaround.

In response, we're increasing maintenance spend on our assets, ramping up employee training, and leveraging more resources from our other facilities. As demand remains strong, we are utilizing our other plants within our network to offset any production shortfall. In light of price increases in the marketplace, we believe it's vital to continue supporting our brands through targeted innovation and marketing. Accordingly, we're seeing strong distribution across our customer base for newly launched Bonterra, our sustainable product family. Speed to shelf has been very quick for this new brand. Our recently upgraded Purex and Cashmere UltraLuxe TAD products are also tracking well against expectations, while second year of SpongeTowels UltraPro continues to drive share with consumers. More recently, we expanded the distribution and support of our newly relaunched White Cloud portfolio in the US.

Finally, on the heels of more than 80% growth for our e-commerce channels in 2021, our internal estimates indicate that we continue to increase share in this channel, reflecting a 2-point share increase in e-com. The data presented on slide 11 is from Nielsen. It shows solid market share performance over a 52-week period, ending on March 23rd, 2022. Amidst the market recovery, we continue expanding in the facial tissue and paper towel categories, with shares of 36.2% and 24.1%, respectively. As for bathroom tissue, we have maintained our share above 34% as we had some competitor recapture post-COVID. On slide 12, the away from home market in Canada continued to pick up in Q1 2022, while the U.S. market has fully recovered from the COVID-19 pandemic.

We estimate volume was approximately 30% better in the first quarter of 2022 than Q1 2021 levels. Rising inflation for raw materials, transportation, and labor negatively affected AFH profitability in Q1 2022, as price increases lagged cost inflation. Further price increases in AFH became effective in May, allowing us to create a better EBITDA profile for this segment in the second half of the year. With that, I will now turn the call over to Mark.

Mark Holbrook
CFO, KP Tissue Inc

Thank you, Dino, and good morning, everyone. Please turn to slide 13 for a summary of our financial performance in Q1 2022. Revenue increased 28.5%, CAD 398.7 million in the first quarter of 2022, and from CAD 310.4 million in the first quarter of 2021. On a sequential basis, revenue was down 6% from CAD 424.1 million. Adjusted EBITDA was CAD 29.1 million in Q1 2022, lower by CAD 8.4 million from CAD 37.5 million in the same period last year, and down CAD 9.2 million sequentially from CAD 38.3 million in Q4 2021.

From a margin perspective, Adjusted EBITDA amounted to 7.3% in Q1 2022, compared to 12.1% in Q1 last year, and 9% in Q4 2021. In the first quarter of 2022, net income totaled CAD 1.4 million, compared to CAD 6.8 million for the same period last year. The CAD 5.4 million decrease was primarily due to lower Adjusted EBITDA, higher interest expense and other finance costs, and higher depreciation and amortization, partly offset by higher income tax recovery and higher other income. In the quarterly segmented view on Slide 14, consumer revenue increased 26.3% year-over-year, but decreased 5.8% sequentially to CAD 342.8 million in the first quarter of 2022.

In the away from home segment, revenue grew 43.3% year-over-year, while posting a 7% sequential decrease to CAD 55.9 million. Consumer adjusted EBITDA amounted to CAD 35.4 million in the first quarter of 2022, compared to CAD 44.1 million in Q1 2021, while adjusted EBITDA margin was 10.3% and 16.2% for the same periods, respectively. Sequentially, consumer-adjusted EBITDA was down by CAD 8.3 million, while the margin reduction was limited to 1.7 margin points. For the AFH segment, adjusted EBITDA amounted to -CAD 3.2 million in the first quarter of 2022, compared to -CAD 4.8 million in the first quarter of 2021, and -CAD 1.7 million in Q4 2021.

Corporate and other costs were -CAD 3.1 million in Q1, 2022, compared to -CAD 1.8 million for the same period last year, and -CAD 3.7 million for Q4, 2021. On Slide 15, we review the year-over-year revenue growth for Q1, 2022, which amounted to CAD 88.3 million or 28.5%. This increase can be attributed to selling price increases in all segments and regions.... higher consumer sales volume, as well as an increase in away from home sales volume. On a geographical basis, revenues in Canada improved CAD 48.3 million, or 24.8% year-over-year, while U.S. revenues grew by CAD 40 million, or 34.6%.

On slide 16, we provide additional insight into our Q1 2022 adjusted EBITDA, which decreased year-over-year by CAD 8.4 million, or 22.4% to CAD 29.1 million. The adjusted EBITDA margin was 7.3% in Q1 2022, compared to 12.1% in Q1 2021. The decrease in adjusted EBITDA dollars was primarily due to higher pulp prices and overall inflation, which also resulted in higher freight rates, unfavorable impacts from overhead absorption and labor shortages at our Memphis manufacturing operations. These factors were partially offset by a higher sales volume and selling price increases. Now let's turn to slide 17, where we compare revenue in Q1 2022 to Q4 2022. Revenue decreased by CAD 25.4 million, or 6% sequentially.

This decline was mainly due to lower seasonal Q1 volume in both consumer and Away-from-Home segments. In terms of geography, revenue in Canada decreased by CAD 2.3 million, or 0.9%, while revenue in the U.S. declined by $23.1 million, or 12.9%. On slide 18, Q1 2022 Adjusted EBITDA decreased sequentially by CAD 9.2 million, or 24.2% from Q4 of 2021. This was due to the lower sales volume, higher pulp prices and inflation, increased freight costs, labor challenges in Memphis, increased overhead absorption, and a loss on foreign exchange, which was partially offset by a reduction in advertising expenses, as well as selling price increases in consumer U.S. and Away-from-Home. The Adjusted EBITDA margin was 7.3% in Q1 2022, compared to 9% in the previous quarter.

Let's turn now to our balance sheet and financial position on slide 19. Our cash position stood at CAD 113.7 million at the end of Q1, 2022, a decrease from CAD 151 million at the end of Q4, 2021. The reduction in cash mainly reflects a CAD 46.5 million increase in working capital during the quarter. Overall, total debt at quarter end stood at CAD 985.5 million, up CAD 16.6 million from CAD 968.9 million at the end of Q4. Variation is primarily attributable to the aforementioned increase in working capital. Our net debt to last twelve months Adjusted EBITDA leverage ratio increased to 6x in Q1, 2022 from 5.3x in Q4, 2021.

Leverage increased due to the higher level of net debt from a lower cash position and lower last twelve months adjusted EBITDA. At quarter end, total liquidity, representing cash and cash equivalents and availability from revolving credit agreements, stood at CAD 206.9 million. In addition, CAD 76.4 million of cash was held for the TAD Sherbrooke and Sherbrooke expansion projects. I will conclude my section by reviewing CapEx on slide 20. CapEx amounted to CAD 16.3 million in Q1 2022, including CAD 5.3 million for TAD Sherbrooke and CAD 6 million for the Sherbrooke expansion project. We now expect CapEx to range between CAD 160 million and CAD 180 million in 2022, including incremental investments announced for the Sherbrooke expansion project.

These figures represent a CAD 30 million reduction from our previous range, attributable to both deferrals and schedule revisions for certain capital investments. Thank you for joining us this morning, and I'll now turn the call back over to Dino.

Dino Bianco
CEO, KP Tissue Inc

Thank you, Mark. On slide 21, just a brief word about our ESG efforts. Reimagine 2030 reflects our commitment to creating a sustainable environment, but we're also focused on social and governance issues. All three elements are inextricably linked with our strategic plan to create long-term value for our shareholders, our stakeholders, and our employees. We will continue to build our actions against this framework. I will conclude on slide 22. Our main goal is to grow the business for the long term while managing current inflationary pressure. In that context, we continue to deliver strong top-line growth despite a challenging environment. We expect our price increases and cost efficiencies to begin offsetting inflation pressure in the second half of 2022. In terms of marketing, newly launched Bonterra and the Ultra Luxe upgrade are tracking well above expectations.

We also expanded the distribution of a relaunched White Cloud portfolio in the U.S., and we are supporting these latest initiatives by investing in our brands and innovation to drive growth. For our network modernization, the TAD Sherbrooke facility continues to ramp up ahead of expectation, while the Memphis turnaround plan is expected to yield benefits in the second half of the year. Our away from home segment is gradually recovering in Canada and will benefit from price increase in the second half of the year while continuing to grow in the U.S. And finally, we continue to invest in our organization and culture to drive growth for the future. Now, turning our attention to the outlook for the second quarter of 2022. We anticipate continued sales momentum in Q2 2022 for both our consumer and AFH segments.

However, ongoing and rapid cost inflation and supply chain issues are expected to negatively impact our profit. As a result, Adjusted EBITDA for the second quarter of 2022 is expected to be well below the Q1 2022 level, with pricing and cost savings initiatives improving our overall outlook in the second half of the year. We will now be happy to take your questions.

Operator

Thank you. If you would like to ask a question, please press star, followed by one on your telephone keypad. If you wish to remove yourself from the queue, please press star one again. One moment, please, for your first question. Your first question comes from the line of Hamir Patel of CIBC Capital Markets. Please go ahead.

Hamir Patel
Executive Director of Equity Research, CIBC Capital Markets

Hi, good morning Dino.

Dino Bianco
CEO, KP Tissue Inc

Morning, Hamir.

Hamir Patel
Executive Director of Equity Research, CIBC Capital Markets

Could you speak to the timing of the various price initiatives you have in the market across categories and geographies, and any scale you could provide on those?

Dino Bianco
CEO, KP Tissue Inc

Yeah, I mean, that's a great question. Obviously, with the level of inflation, I guess, the speed, the breadth and the magnitude of the inflation, pricing is a necessary offset to that, as well as the cost cuts that I talked about. We did do pricing last year in Canada, Consumer Canada. I mentioned that it was mid- to high-single digits. That took effect last July. We did some contractual pricing in the US and AFH in the back half of last year. And then, in 2022, we've recently announced a new price increase in Canada to catch up to all the additional inflation, high-single digit that'll take effect beginning in July.

U.S., we've announced a couple of price increases, depending on the customer contracts, that are probably in the mid single digits, let's say, a couple of points behind the Canadian one. Just different market dynamics there. And then AFH has also announced two separate price increases this year in the mid to high single digits, also affecting the back half. Most of those, some will come in April, a little more in May, and then really July is when they start to hit, just given the structural way that pricing flows through the North American market for our business.

Hamir Patel
Executive Director of Equity Research, CIBC Capital Markets

Great. Thank you, Dino. That's. It's really helpful. And I just wanna get your perspective on the U.S. supply situation. You know, it does seem like operating rates are probably suboptimal right now across a lot of the private label markets. Are you expecting more supply rationalization later this year? I know there's at least one mill that's for sale.

Dino Bianco
CEO, KP Tissue Inc

Yeah, that's a great, it's a great question. You know, I read all the reports, and, you know, there's obviously, at the macro level, there seems to be more capacity than demand. I will tell you that's not the case for our business. Our business is very strong. In fact, we're ramping everything up. Despite Memphis being behind our plan, we're ramping up to continue to satisfy the marketplace. So, you know, it's hard for me to comment on long-term supply, demand. I think ultimately it will balance. You've heard of one mill for sale. There's you know, I think that may not just be a capacity issue, it may be just a cost structure issue as inflation's, I think, affecting a lot of companies, differently.

So I think, you know, companies will have to make their own decision as it relates to either new capacity or exiting capacity. In my mind, Hamir, you know, I continue to see robust growth in this category. I continue to see it in Canada and the U.S. and in AFH, so all three segments that we play in. I think the U.S. market, you know, recently, private label has been a little stronger, so we're, you know, we're watching that. And of course, you know, we participate in that growth.

In Canada, our brands continue to be strong in this marketplace. It's, I think, a testament to the investments we've made in our brands and the quality over the time. So, you know, I feel good about the demand curve. For me, it's the cost curve that's been the biggest challenge, and we're dealing with a lag. We'll catch up, but we're dealing with a lag right now, which is affecting the first half of this year.

Hamir Patel
Executive Director of Equity Research, CIBC Capital Markets

Okay, fair enough. You know, just last question I have is on White- the White Cloud relaunch. It looks like you're now in Publix. Is that the only major U.S. grocer customer at the moment? And maybe if you could speak to the plans for distribution there.

Dino Bianco
CEO, KP Tissue Inc

You know, Hamir, I wish I could talk a lot more about White Cloud. We're really proud of what we're doing, but, you know, I also recognize that our competition listens to these calls, so I think I just wanna say that, you know, it's a brand we believe in. We've restaged the brand. We've upped the quality. We're investing to support it. We think there's a sweet spot for that brand in parts of the US market. We have and are increasing distribution at some key accounts with that business. So, you know, just stay tuned and keep watching it.

Hamir Patel
Executive Director of Equity Research, CIBC Capital Markets

Okay, fair enough. Thanks, Dino. That's, that's all I had. I'll, I'll turn it over.

Dino Bianco
CEO, KP Tissue Inc

Thank you.

Operator

Your next question comes from the line of Kasia Kopytek of TD Securities. Please go ahead.

Kasia Kopytek
Equity Research Associate, TD Securities

Hi, good morning, everyone. First question, back to Hamir's question on price, price hike that you've implemented and you're planning to implement. I think I read in your disclosures that you expect those pricing initiatives to restore margins. Dino, if you could maybe speak to what level you expect those margins to be restored to, and I appreciate you may be reluctant to give us an actual number, but maybe if you could just speak to it qualitatively, that would be helpful as well.

Dino Bianco
CEO, KP Tissue Inc

You know, Kasia, you were cutting in and out, so I'm not sure I totally understood the question, but let me answer what I think you asked, which is, you know, how does pricing affect our margin structure, and what are we looking at from a margin point of view? I would say that, you know, as I mentioned, with the last question from Hamir, what you're seeing here over the last 12, 18 months, is a rapid, broad, and significant increase in inflation. And even though we, like many companies, have tried to catch up to it, either through pricing and/or cost cutting, you just can't catch up to that speed. So you're seeing a lagged effect, and that's affecting our margin structure of our products.

But we are affecting pricing that will take... You know, we think, we think inflation is peaking, although, you know, it's hard to predict anything in this day and age. But we think what we're seeing is a lot of the inflation is peaking. Pulp and fiber continue to be a bit of a wild card, but we think things like freight and packaging are peaking. Energy, it's hard to tell as well, but that has less of an impact on our total business. So, you know, we're watching them closely.

We think we have priced to restore our historical margins. We're not really doing this to go beyond and above that. We don't think the market will allow us to. We made some portfolio adjustments just for brands that were perhaps maybe not at the level we wanted to, so we made some tweaking along our portfolio, both in the U.S. and Canada, around margin structure. But we expect after this pricing, and assuming inflation is peaking and stabilizing, that we should be in a position to restore margins.

Kasia Kopytek
Equity Research Associate, TD Securities

Great. Thanks for that, Dino. Sorry about the poor connection. I'm not sure if it's better now. But, one more question, maybe for Mark. I know CapEx has been lowered, and you said that's both a, a deferral and, just a reduction in planned spending. Any additional context you can provide as to where those reductions are coming from, which, which projects? And I assume the Sherbrooke expansion is still the CAD 350 million that was originally guided to, right?

Mark Holbrook
CFO, KP Tissue Inc

Yes, that's correct, Kasia. So, the Sherbrooke expansion, we haven't really changed that at all. As you know, that project goes out through 2024, so it's progressing well and on time, on budget. We're not, we're not changing anything there. We are seeing some inflationary effect on that project, but we still feel it's it can be within the total bundle that we've set out for everyone. On the rest of our CapEx, or our regular CapEx, that we've decided to defer some of that CapEx going forward, and so that will be pushed into 2023, and that's what you're seeing there. So majority of that, we had a fairly substantial list of projects this year, and we're just pushing them out.

Kasia Kopytek
Equity Research Associate, TD Securities

Okay, great. Thanks, Mark. I appreciate the context. I'll get back in the queue.

Mark Holbrook
CFO, KP Tissue Inc

Thank you.

Operator

Thank you, ladies and gentlemen. Again, if you have a question, please press star followed by one on your telephone keypad. Your next question comes from the line of Zachary Evershed of National Bank Financial. Please go ahead.

Nathan Po
Equity Research Associate, National Bank Financial

Morning, everyone. It's actually Nathan calling in for Zach.

Dino Bianco
CEO, KP Tissue Inc

Morning.

Mark Holbrook
CFO, KP Tissue Inc

Morning, Nathan.

Nathan Po
Equity Research Associate, National Bank Financial

My first question is, with pulp soaring off like a rocket, do you think it will remain elevated once freight logjams unsnarl?

Dino Bianco
CEO, KP Tissue Inc

Well, I put my crystal ball away a few months ago, Nathan. I've given up trying to project where these things are going. I mean, you know, people a lot smarter than me and closer to this market are having difficulty predicting it. So our approach has been, we need to be agile, we need to be flexible, we need to be ready both on the pricing front and the cost-cutting front to be able to adapt as it moves. I believe it's peaking. I believe you've got supply chain challenges happening. There is probably a knock-on effect of the war in Russia.

I believe you've got cost of production going up, and I believe you've got just the general inflation, fiber, fiber costs, relative to what's going on in every other commodity in the marketplace. Ultimately, supply and demand will determine, you know, where the real cost settles out. I know we've got some new capacity coming on board, so that may be more of a bearish sign in the back half. But at this point, all I can tell you is, you know, we're projecting it to stay at fairly high levels, both NBSK and BEK. And then the other one I didn't really talk about, because it is a core ingredient for us, is sorted office paper. Also, significant cost increases on that one, even more on a magnitude basis than what we're seeing on pulp.

Nathan Po
Equity Research Associate, National Bank Financial

All right. Thanks. And for in terms of this inflationary environment, are you concerned about customers swapping to Private Label tissue?

Dino Bianco
CEO, KP Tissue Inc

Yeah, I mean, that's always a watchout, for sure. In the U.S., you know, we're more of a private label supplier. I think that will benefit us, and we've seen a little more escalation there. The Canadian market is generally overdeveloped versus the U.S. on private label already, so we haven't seen as dramatic a shift there. Bathroom tissue we did, but I think a lot of that was driven by just post-COVID recovery of some of those competitors, including private label. We watch it. We watch our price gaps. We have a portfolio of products that span different quality spheres and different sizes, so we can manage our price points accordingly for consumers.

We gotta make sure that our price gaps stay in line, and we gotta make sure we continue to invest to support our brands. You know, we're not taking an approach where we're gonna be cutting our marketing spend significantly at a time when we're doing price increases. We wanna make sure we're continuing to invest in making our brands relevant. So some we'll continue to watch very closely, particularly around the price gap movement and the promotion strategies that are going on in the marketplace.

And then, of course, you also got channel mixing. I think a lot of the retailers talked about this in terms of consumer growth moving to different channels, whether it be discount or mass or club, and we'll just watch that we're relevant in those channels where the consumer's going.

Nathan Po
Equity Research Associate, National Bank Financial

All right. Thank you for the context. I'll turn it over.

Operator

There are no further questions at this time. I will turn the call back to Mr. Dino Bianco.

Dino Bianco
CEO, KP Tissue Inc

Thank you, and thank you all for joining us on this call today. We look forward to speaking with you again following the release of our second quarter results. Thank you. Have a great day.

Operator

Ladies and gentlemen, this concludes today's conference call. You may now disconnect.

Powered by